Correspondence 0001193125-24-212054 from BioAge Labs, Inc. (BIOA) (CIK 0001709941) (BIOA)
BioAge Labs, Inc. (BIOA) (CIK 0001709941)
Date: Sept. 3, 2024 · CIK: 0001709941 · Accession: 0001193125-24-212054
AI Filing Summary & Sentiment
Referenced dates: August 9, 2024
Letter
September 3, 2024
VIA EDGAR AND ELECTRONIC TRANSMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, DC 20549
Attention:
Eric Atallah
Vanessa Robertson
Jimmy McNamara
Joshua Gorsky
Re:
BioAge Labs Inc.
Amendment No. 2 to Draft Registration Statement on Form S-1
Submitted August 5, 2024
CIK No. 0001709941
Ladies and Gentlemen:
We are submitting this letter on behalf of BioAge Labs, Inc. (the “Company”) in response to the comment of the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) contained in the Staff’s letter dated August 9, 2024 (the “Letter”), regarding the Company’s Amendment No. 2 to Draft Registration Statement on Form S-1 (CIK No. 0001709941) confidentially submitted by the Company to the Commission on August 5, 2024 (the “Draft Registration Statement”). Concurrently, we are transmitting herewith and filing a copy of the Company’s Registration Statement on Form S-1 (the “Registration Statement”). The numbered paragraph below corresponds to the numbered comment in the Letter and the Staff’s comment is presented in bold italics.
In addition to addressing the comment raised by the Staff in the Letter, the Company has revised the Registration Statement to update certain other disclosures. Capitalized terms used and not otherwise defined herein have the same meanings as specified in the Registration Statement.
U.S. Securities and Exchange Commission
September 3, 2024
Page 2
Amendment No. 2 to Draft Registration Statement on Form S-1
Business
Indication expansion opportunities, page 143
1. We note your response to comment 3 and re-issue in part. Please disclose who conducted the third-party cross-over trial, whether it was preclinical or clinical, and specify the third-party preclinical literature.
In response to the Staff’s comment, the Company has revised its disclosure on page 144 of the Registration Statement to confirm the third-party cross-over trial disclosed was a clinical trial conducted by Institut National De La Sante Et De La Recherche Medicale. The Company also revised its disclosures to cite the third-party preclinical literature referenced in the Registration Statement.
* * * * * * *
Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact me at (415) 875-2420, or in my absence, Robert Freedman at (206) 389-4524.
Sincerely,
/s/ Julia Forbess
Show Raw Text
CORRESP 1 filename1.htm CORRESP September 3, 2024 VIA EDGAR AND ELECTRONIC TRANSMISSION U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Eric Atallah Vanessa Robertson Jimmy McNamara Joshua Gorsky Re: BioAge Labs Inc. Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted August 5, 2024 CIK No. 0001709941 Ladies and Gentlemen: We are submitting this letter on behalf of BioAge Labs, Inc. (the “Company”) in response to the comment of the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) contained in the Staff’s letter dated August 9, 2024 (the “Letter”), regarding the Company’s Amendment No. 2 to Draft Registration Statement on Form S-1 (CIK No. 0001709941) confidentially submitted by the Company to the Commission on August 5, 2024 (the “Draft Registration Statement”). Concurrently, we are transmitting herewith and filing a copy of the Company’s Registration Statement on Form S-1 (the “Registration Statement”). The numbered paragraph below corresponds to the numbered comment in the Letter and the Staff’s comment is presented in bold italics. In addition to addressing the comment raised by the Staff in the Letter, the Company has revised the Registration Statement to update certain other disclosures. Capitalized terms used and not otherwise defined herein have the same meanings as specified in the Registration Statement. U.S. Securities and Exchange Commission September 3, 2024 Page 2 Amendment No. 2 to Draft Registration Statement on Form S-1 Business Indication expansion opportunities, page 143 1. We note your response to comment 3 and re-issue in part. Please disclose who conducted the third-party cross-over trial, whether it was preclinical or clinical, and specify the third-party preclinical literature. In response to the Staff’s comment, the Company has revised its disclosure on page 144 of the Registration Statement to confirm the third-party cross-over trial disclosed was a clinical trial conducted by Institut National De La Sante Et De La Recherche Medicale. The Company also revised its disclosures to cite the third-party preclinical literature referenced in the Registration Statement. * * * * * * * Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact me at (415) 875-2420, or in my absence, Robert Freedman at (206) 389-4524. Sincerely, /s/ Julia Forbess Julia Forbess Partner FENWICK & WEST LLP cc: Kristen Fortney, Chief Executive Officer and President BioAge Labs, Inc. Robert Freedman, Esq. Matthew Rossiter, Esq. Michael Pilo, Esq. Fenwick & West LLP Charlie S. Kim, Esq. Denny Won, Esq. Divakar Gupta, Esq. Cooley LLP